Skip to main content
    E

    Evogene (EVGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.34
    -0.05 (-13.17%)

    Market Cap: $6.70M

    Last updated: Nov 17, 2026 at 4:39 PM ET

    Evogene (EVGN) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Evogene (EVGN) has a market cap of $6.70M. It kept -694.19% of revenue as net income over the last 12 months. Its share count is up 68.84% from a year earlier.

    Total Valuation

    Market Cap$6.70M
    Latest price (Nov 17, 2026)$0.34

    Key Dates

    The next earnings report is expected on Nov 18, 2026, covering the quarter ending Sep 30, 2026.

    Next Earnings DateNov 18, 2026 (expected)
    Last Earnings DateAug 18, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 25.28% in the quarter ended Jun 30, 2026 and grew 54.80% a year over 2 years.

    Shares Outstanding12.20M
    Shares Change (YoY)+68.84%
    Shares Change (QoQ)+25.28%
    Share Count Growth (2Y CAGR)+54.80%

    Valuation Ratios

    The price to sales ratio is 3.2x. Its year-end P/S ranged from 1.3x to 519.9x from 2016 to 2025.

    P/S Ratio3.2x
    Forward P/S4.7x

    Price Statistics

    The stock is down 71.89% over 52 weeks and trades 15.00% below its 50-day average.

    Beta (1Y)1.29
    52-Week Change-71.89%
    1-Month Change-7.58%
    3-Month Change-43.40%
    6-Month Change-54.29%
    5-Year Change-98.56%
    10-Year Change-99.38%
    Total Return (1Y)-71.89%
    Total Return (3Y CAGR)-62.78%
    Total Return (5Y CAGR)-56.18%
    Max Drawdown (1Y)-77.42%
    Max Drawdown (3Y)-97.23%
    Sharpe Ratio (1Y)-1.45
    Correlation with SPY (1Y)0.21
    50-Day Average$0.40
    200-Day Average$0.62
    52-Week Range$0.25 to $1.26
    RSI (14 Days)44.6
    Average Volume (20 Days)584.88K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.57x current liabilities.

    Current Ratio3.57x
    Quick Ratio3.54x
    Interest Coverage-2.77x

    Returns and Efficiency

    Return on Assets (ROA)-67.51%
    Return on Capital Employed (ROCE)-129.47%
    ROA (5Y Average)-42.86%
    Asset Turnover0.06x
    Inventory Turnover21.84x
    Receivables Turnover1.25x
    Cash Conversion Cycle255 days

    Scores

    EVGN has an Altman Z-Score of -32.41, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-32.41
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $1.31M over the last 12 months is down 80.43% from the 12 months before.

    Revenue$1.31M
    Revenue Growth (YoY)-80.43%
    Gross Profit-$1.62M
    Operating Income-$13.53M
    Pretax Income-$15.56M
    Net Income-$9.07M
    EBITDA-$12.56M
    EBIT-$13.46M
    Reported EPS (TTM)-$1.82

    Trailing 12 months through Jun 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$9.35M
    Working Capital$7.81M
    Shareholder Equity-$3.29M
    Total Assets$13.44M
    Total Liabilities$7.67M

    Balance sheet as of Jun 30, 2026.

    Full balance sheet

    Cash Flow

    After $28.66K of capital spending, operating cash flow left -$11.56M of free cash flow.

    Operating Cash Flow-$11.54M
    Capital Expenditures$28.66K
    Free Cash Flow-$11.56M
    FCF Per Share-$0.64
    Depreciation and Amortization$895.00K

    Trailing 12 months through Jun 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -1034.97%.

    Gross Margin-123.87%
    Operating Margin-1034.97%
    Pretax Margin-1190.74%
    Net Margin-694.19%
    EBITDA Margin-961.36%
    EBIT Margin-1029.84%
    FCF Margin-884.79%
    Gross Margin (5Y Average)32.87%

    Growth

    Revenue grew 32.01% a year over 3 years.

    Revenue Growth (3Y CAGR)+32.01%
    Revenue Growth (5Y CAGR)+29.94%

    Revenue and profit by year

    Dividends and Yields

    EVGN does not pay a dividend. Its free cash flow yield is -278.71%.

    FCF Yield-278.71%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 1-for-10 reverse split on Jul 25, 2024.

    Last Split DateJul 25, 2024
    Split TypeReverse split
    Split Ratio1:10

    Peer Position

    Against 6 similar companies, EVGN has the 6th highest P/S.

    P/S Ratio3.2x vs 9.8x median
    Revenue Growth (Trailing 4 Quarters, YoY)-80.43% vs -63.21% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -17.85% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-17.85%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About EVGN

    What is EVGN's market cap?

    Evogene has a market cap of $6.70M.

    How many shares of EVGN are outstanding?

    Evogene has 12.20M shares outstanding. The count is up 68.84% from a year earlier.

    Does EVGN pay a dividend?

    No. Evogene does not pay a dividend.